• About
    • Mission, Vision and Values
    • Team
    • Board of Directors
    • Investors
  • Pipeline
  • VICOMER™ Platform
    • VICOMER™ Platform
    • Scientific Publications
    • Collaborators
  • News
  • Join Our Team
  • Contact Us
VICO Therapeutics
Vico Therapeutics Appoints Scott Schobel, MD as Chief Medical Officer

Vico Therapeutics Appoints Scott Schobel, MD as Chief Medical Officer

by VICO Therapeutics | Oct 3, 2022 | Management, Press Release

Dr. Schobel joins Vico from Roche where he was the clinical science leader for tominersen being developed for Huntington’s disease LEIDEN, Netherlands, October 3, 2022 – Vico Therapeutics B.V., a neurology-focused genetic medicine company, today announced the...
Vico Therapeutics Appoints Micah Mackison as Chief Executive Officer

Vico Therapeutics Appoints Micah Mackison as Chief Executive Officer

by VICO Therapeutics | Aug 4, 2022 | Management, Press Release

LEIDEN, Netherlands, Aug. 1, 2022 /PRNewswire/ — Vico Therapeutics B.V., a neurology-focused genetic medicine company, today announced the appointment of Micah Mackison as Chief Executive Officer. Mr. Mackison brings significant biotechnology and pharmaceutical...
US FDA grants VICO Therapeutics Orphan-Drug Designation for VO659, an Investigational Therapy for Huntington Disease

US FDA grants VICO Therapeutics Orphan-Drug Designation for VO659, an Investigational Therapy for Huntington Disease

by VICO Therapeutics | Jul 29, 2021 | Press Release

Leiden, The Netherlands, 29 July 2021 –  VICO Therapeutics,a Leiden Bio Science Park, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced that the Office of Orphan...
US FDA grants VICO Therapeutics Orphan-Drug Designation for VO659, an Investigational Therapy for Spinocerebellar Ataxia

US FDA grants VICO Therapeutics Orphan-Drug Designation for VO659, an Investigational Therapy for Spinocerebellar Ataxia

by VICO Therapeutics | Jun 29, 2021 | Press Release

Leiden, The Netherlands, 29 June 2021 –  VICO Therapeutics,a Leiden, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced that the Office of Orphan Products...
European Commission grants VICO Therapeutics Orphan Drug Designation for VO659, an Investigational Therapy for Spinocerebellar Ataxia

European Commission grants VICO Therapeutics Orphan Drug Designation for VO659, an Investigational Therapy for Spinocerebellar Ataxia

by VICO Therapeutics | Feb 10, 2021 | Press Release

Leiden, The Netherlands, 10 February 2021 – VICO Therapeutics, a Leiden, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced that the European Commission (EC) has granted...
Biotech VICO Therapeutics raises $31 million (€27 million) in Series A financing round to advance therapies for rare central nervous system diseases

Biotech VICO Therapeutics raises $31 million (€27 million) in Series A financing round to advance therapies for rare central nervous system diseases

by VICO Therapeutics | Jul 29, 2020 | Press Release

AON-platform with focus on therapies nearing phase I trials for forms of Spinocerebellar Ataxia and Huntington Disease Other early discovery stage RNA editing platform focuses on RETT syndrome Funding led by LSP, co-led by Kurma Partners, supported by Pontifax, Droia...

© 2022 VICO Therapeutics | All rights reserved | Privacy statement


Designed and developed by Root Agency
This website uses strictly necessary cookies to enable the website to function, namely to secure our website and to save certain preferences and repeat visits, including recording your cookies preferences. If you agree, we would also like to use non-essential cookies to enable us to observe traffic levels to the website which allows us to understand interaction with the website and helps us to improve the website and our services. To learn more about this, visit our Cookie Policy. You may consent to the use of non-essential cookies by clicking “Accept Cookies” or "Decline Cookies" by closing the cookie with the x-symbol above.
Accept Cookies
Read more
Change Settings
Cookie Box Settings
Cookie Box Settings

Privacy settings

Decide which cookies you want to allow. You can change these settings at any time. However, this can result in some functions no longer being available. For information on deleting the cookies, please consult your browser’s help function. Learn more about the cookies we use.

With the slider, you can enable or disable different types of cookies:

  • Block all
  • Essential
  • Analytics
  • Hide details
  • Save & Close
  • Block all
  • Essentials
  • Analytics

This website will:

  • Essential: Remember your cookie permission setting
  • Essential: Allow session cookies
  • Essential: Gather information you input into a contact forms, newsletter and other forms across all pages

This website won't:

  • Remember your login details
  • Functionality: Remember social media settings
  • Functionality: Remember selected region and country
  • Analytics: Keep track of your visited pages and interaction taken
  • Analytics: Keep track about your location and region based on your IP number
  • Analytics: Keep track of the time spent on each page
  • Analytics: Increase the data quality of the statistics functions
  • Advertising: Tailor information and advertising to your interests based on e.g. the content you have visited before. (Currently we do not use targeting or targeting cookies.
  • Advertising: Gather personally identifiable information such as name and location

This website will:

  • Essential: Remember your cookie permission setting
  • Essential: Allow session cookies
  • Essential: Gather information you input into a contact forms, newsletter and other forms across all pages
  • Functionality: Remember selected region and country

This website won't:

  • Remember your login details
  • Analytics: Keep track of your visited pages and interaction taken
  • Analytics: Keep track about your location and region based on your IP number
  • Analytics: Keep track of the time spent on each page
  • Analytics: Increase the data quality of the statistics functions
  • Advertising: Tailor information and advertising to your interests based on e.g. the content you have visited before. (Currently we do not use targeting or targeting cookies.
  • Advertising: Gather personally identifiable information such as name and location

This website will:

  • Essential: Remember your cookie permission setting
  • Essential: Allow session cookies
  • Essential: Gather information you input into a contact forms, newsletter and other forms across all pages
  • Functionality: Remember social media settingsl Functionality: Remember selected region and country
  • Analytics: Keep track of your visited pages and interaction taken
  • Analytics: Keep track about your location and region based on your IP number
  • Analytics: Keep track of the time spent on each page
  • Analytics: Increase the data quality of the statistics functions
  • Analytics: Use information for tailored advertising with third parties
  • Analytics: Identify device you are using
  • Analytics: Gather personally identifiable information such as name and location

This website won't:

  • Remember your login details
  • Advertising: Allow you to connect to social sites

This website will:

  • Essential: Remember your cookie permission setting
  • Essential: Allow session cookies
  • Essential: Gather information you input into a contact forms, newsletter and other forms across all pages
  • Analytics: Keep track of your visited pages and interaction taken
  • Analytics: Keep track about your location and region based on your IP number
  • Analytics: Keep track of the time spent on each page
  • Analytics: Increase the data quality of the statistics functions
  • Analytics: Identify device you are using
  • Contact: Gather personally identifiable information such as name and location

This website won't:

  • Remember your login details
Save & Close